TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00664716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baminercept alfa 1
Description: experimental - one dose level

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baminercept alfa 2
Description: experimental - second dose level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baminercept alfa 3
Description: experimental - third dose level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baminercept alfa 4
Description: experimental - fourth dose level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Baminercept alfa 5
Description: experimental - fifth dose level
Study: NCT00969787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP05195
Description: tablets, oral administration, single and multiple administrations
Study: NCT02279186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Intravenous Injection
Study: NCT04156815

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 1,565nm NAFL
Description: 1,565nm M22-ResurFx NAFL can deliver additional benefits to existing acne scar and skin texture. Patients were first treated by the 1,565nm M22-ResurFx NAFL on inflammatory papules and boxcar atrophic scars using round or rectangle light spots with similar sizes of individual lesional papules or scars. The energy fluence was 60 mJ and spot density was 150 spots/cm2. A whole face pass treatment was followed using hexagon or rectangle light spots with fluences of 40-45 mJ, density of 200 spots/cm2 and no overlap on light spots. The end points of the treatment were appearance of localized erythema, edema and bruise on treated areas.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 1,565nm NAFL
Description: 1,565nm M22-ResurFx NAFL can deliver additional benefits to existing acne scar and skin texture. Patients were first treated by the 1,565nm M22-ResurFx NAFL on inflammatory papules and boxcar atrophic scars using round or rectangle light spots with similar sizes of individual lesional papules or scars. The energy fluence was 60 mJ and spot density was 150 spots/cm2. A whole face pass treatment was followed using hexagon or rectangle light spots with fluences of 40-45 mJ, density of 200 spots/cm2 and no overlap on light spots. The end points of the treatment were appearance of localized erythema, edema and bruise on treated areas.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 1,565nm NAFL
Description: 1,565nm M22-ResurFx NAFL can deliver additional benefits to existing acne scar and skin texture. Patients were first treated by the 1,565nm M22-ResurFx NAFL on inflammatory papules and boxcar atrophic scars using round or rectangle light spots with similar sizes of individual lesional papules or scars. The energy fluence was 60 mJ and spot density was 150 spots/cm2. A whole face pass treatment was followed using hexagon or rectangle light spots with fluences of 40-45 mJ, density of 200 spots/cm2 and no overlap on light spots. The end points of the treatment were appearance of localized erythema, edema and bruise on treated areas.
Study: NCT00635752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TF-CBT
Description: TF-CBT sessions will include trauma-focused treatment, and will teach participants behavioral and coping skills.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Participants will receive regular therapy as is usually practiced in clinics
Study: NCT02697136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CER-001
Description: Recombinant human apoA-I/phospholipid complexes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection, USP
Study: NCT03770156

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Overall Impression of the current state and evolution since the attacks
Study: NCT00101387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar PENS + General Conditioning and Aerobic Exercise
Description: As above

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar PENS
Description: As above

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Lumbar PENS
Description: Identical needle placement as with PENS procedure, but only control needles stimulated for 5 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control PENS + exercise
Description: as above
Study: NCT02327806

Intervention type: DEVICE
Group type: OTHER
Intervention: pulsed electromagnetic field therapy

Intervention type: DEVICE
Group type: OTHER
Intervention: pulsed electromagnetic field therapy

Intervention type: DEVICE
Group type: OTHER
Intervention: pulsed electromagnetic field therapy
Study: NCT04389086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination drug
Description: Induction chemotherapy consists of either three three-weekly cycles of CAPOX (oxaliplatin 130 mg/m2 BSA IV + capecitabine 1000 mg/m2 BSA, orally, twice daily) or four two-weekly cycles of FOLFOX (85 mg/m2 BSA of oxaliplatin IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV). It is left to the discretion of the treating medical oncologist which of the two will be administered. In case of (previous) unacceptable toxicity (physician's discretion) to oxaliplatin, FOLFIRI may be prescribed. FOLFIRI (180 mg/m2 BSA of irinotecan IV + 400 mg/m2 BSA of leucovorin IV + 400 mg/m2 BSA of bolus 5-fluorouracil IV followed by 2400 mg/m2 BSA of continuous 5-fluorouracil IV) consists of four two-weekly cycles.~If a patient has stable or responsive disease, induction chemotherapy will be continued with either one three-weekly cycle of CAPOX or two two-weekly cycles of FOLFOX/FOLFIRI.
Study: NCT00891228

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone
Description: Two individual packets of T Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of T on the skin daily.
Study: NCT04389086

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Concomitant chemotherapy agent: capecitabine~Radiotherapy dose: full course radiotherapy consists of 25x2.0 or 28x1.8 Gy. In case of previous radiotherapy, the radiotherapy dose will consist of 15x2.0 Gy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiotherapy
Description: Concomitant chemotherapy agent: capecitabine~Radiotherapy dose: full course radiotherapy consists of 25x2.0 or 28x1.8 Gy. In case of previous radiotherapy, the radiotherapy dose will consist of 15x2.0 Gy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery locally recurrent rectal cancer
Description: Type of surgery depends on the location of the recurrence and involvement of adjacent structures and is left to the discretion of the operating surgeon.~Intraoperative radiotherapy is optional.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery locally recurrent rectal cancer
Description: Type of surgery depends on the location of the recurrence and involvement of adjacent structures and is left to the discretion of the operating surgeon.~Intraoperative radiotherapy is optional.
Study: NCT03037736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 5-fluorouracil is an antimetabolite that is commonly used in glaucoma surgery to prevent postoperative scaring.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab is an anti-VEGF antibody that is commonly used to prevent or treat neovascularization in retinal disorders.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be used as the placebo.
Study: NCT03602053

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ROTAVAC®
Description: 0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ROTAVAC 5D
Description: 0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix®
Description: 1.5 ml of the liquid vaccine will be administered orally twice at 6 and 10 weeks of age.
Study: NCT00891228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Two individual packets of T Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of T on the skin daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Two individual packets of T Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of T on the skin daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nestorone®
Description: Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg Nestorone® mL gel) by pressing two times with 2 mL dispenser head.
Study: NCT01880359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Study: NCT00891228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nestorone®
Description: Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nestorone®
Description: Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.
Study: NCT00904488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Addition of oral Metolazone
Description: Addition of oral metolazone 5 mg daily to continued current dose of intravenous bolus furosemide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide dose escalation
Description: Furosemide dose escalation via either IV bolus (2-2.5 x current dose) or continuous infusion (2-2.5 x current dose administered over previous 24 hours)
Study: NCT03415945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Description: All study participants have a clinical indication for CRT and will receive CRT implantation as part of their routine medical care. Additionally, participants will receive temporary left and right ventricular septal pacing electrodes and a temporary PressureWire to investigate the acute hemodynamic effect of left ventricular septal pacing, using patients as their own controls.
Study: NCT01599013

Intervention type: DRUG
Group type: OTHER
Intervention: Vinflunine, Gemcitabine
Description: * Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal~* Gemcitabine 750 or 1000 mg/m2, IV administration over 30 minutes (starting dose based on baseline creatinine clearance value), Day 1 and 8 every 3 weeks up to progression or unacceptable toxicity or patient's refusal

Intervention type: DRUG
Group type: OTHER
Intervention: Vinflunine, Carboplatin
Description: * Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal~* Carboplatin AUC 4.5, IV administration over 60 minutes, Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal
Study: NCT02445326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle
Study: NCT01880359

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04156815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral isotretinoin
Description: Oral isotretinoin has remained the most effective medication for moderate-to-severe AV.Subjects received oral isotretinoin (Xingyi Yan'an Pharmaceutical, Shanghai, China) (1mg/kg/d for the first 2-4 weeks and 0.5mg/kg/d for the next 12-14 weeks) for a total of 16 weeks. Serum triglycerides, cholesterol and levels of liver enzymes were monitored every month during oral isotretinoin medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral isotretinoin
Description: Oral isotretinoin has remained the most effective medication for moderate-to-severe AV.Subjects received oral isotretinoin (Xingyi Yan'an Pharmaceutical, Shanghai, China) (1mg/kg/d for the first 2-4 weeks and 0.5mg/kg/d for the next 12-14 weeks) for a total of 16 weeks. Serum triglycerides, cholesterol and levels of liver enzymes were monitored every month during oral isotretinoin medication.
Study: NCT00567359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Oral drug taken daily around the same time. Starting dose is 150mg once daily.
Study: NCT03470207

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-pulmonary embolism follow up protocol
Description: Structured post-pulmonary embolism follow up protocol (outlined in Aim 1)
Study: NCT04156815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral isotretinoin
Description: Oral isotretinoin has remained the most effective medication for moderate-to-severe AV.Subjects received oral isotretinoin (Xingyi Yan'an Pharmaceutical, Shanghai, China) (1mg/kg/d for the first 2-4 weeks and 0.5mg/kg/d for the next 12-14 weeks) for a total of 16 weeks. Serum triglycerides, cholesterol and levels of liver enzymes were monitored every month during oral isotretinoin medication.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pricking blood therapy
Description: Pricking blood therapy (PBT) is a modified acupuncture strategy that is adapted to treat inflammatory related diseases. It has been shown to be effective in treatment of many chronic and acute inflammatory conditions including vasomotor rhinitis, acute herpes zoster and acute gouty arthritis,suggesting a potential efficacy for AV as well. At the end point of each session of laser treatment, an acupuncture practitioner performed a PBT in the areas within 1.5 cm radius of the five facial acupoints (Yintang, Zhukong, Sun, Yingxiang, Cuanzhu) (Figure 1). These areas usually appeared intensive erythema. A facial sheet mask was used to clean the face after PBT, and the face was cooled by air cooler for 10 minutes.
Study: NCT04434131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Study subjects will receive 1 unit (200mL) of SARS-CoV-2 convalescent plasma collected from a single donor who recovered from COVID-19.
Study: NCT01870115

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fiber Pill
Description: This fiber pill has been manufactured to mimic the pill that contains the dietary supplements melatonin (M), strontium citrate (S), vitamin D3 (D) and vitamin K2 (K) in appearance but does not contain the supplements

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin, Strontium citrate, Vitamins D3 and K2
Description: Each pill has been manufactured to contain the dietary supplements 2.5mg melatonin (M), 225mg strontium citrate (S), 1000IU vitamin D3 (D) and 30mcg vitamin K2 (K)
Study: NCT02352623

Intervention type: RADIATION
Intervention: DXA scan
Description: DXA scan

Intervention type: PROCEDURE
Intervention: Clinical examination
Description: Clinical examination
Study: NCT02533492

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vicryl
Description: wound closure with vicryl suture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vicryl plus
Description: wound closure with vicryl plus suture
Study: NCT03058055

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will have unstructured lifestyle activities (normal lifestyle activities without restraint).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Origami
Description: Origami lessons (one hour/week) with daily take home Origami activities to complete

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading
Description: Book club that includes weekly one hour meetings and daily reading assignments
Study: NCT03376737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib (250 mg/d) + Pemetrexed (500 mg/m2)
Study: NCT02828436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision Spectra System
Description: Spinal Cord Stimulation

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise Intervention
Description: Standard Exercise
Study: NCT01247168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2461
Description: oral capsules, continuous dosing and intermittent dosing
Study: NCT01510158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad
Description: Tablets, 200 mg once daily (qd)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad
Description: Tablets, 400 mg qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Placebo qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Allopurinol
Description: Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
Study: NCT00738751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat (LBH589)
Description: Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Each cycle was defined as a 21-day period. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Erlotinib was taken daily without interruption. Each cycle was defined as a 21-day period. Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
Study: NCT02210858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Given PO
Study: NCT03871244

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Less red blood cell transfusions
Description: The instructions given to caregivers will be to consider prescribing a red blood cell transfusion only if the hemoglobin level is ≤ 70 g per L.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: More red blood cell transfusion (standard transfusion strategy in PICU)
Description: The instructions given to caregivers will be to prescribe a red blood cell transfusion according to their usual standard practice
Study: NCT00536471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride
Study: NCT02147041

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01880359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimorazole
Study: NCT02990845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/ Exemestane/ Leuprolide
Description: Dose level 1 (Pembrolizumab 150 mg IV Q2W); Dose level -1 (Pembrolizumab 100 mg IV Q2W); Dose level -2 (Pembrolizumab 50 mg IV Q2W) Combination with Exemestane 25 mg PO QD, and Leuprolide 3.75 mg SC Q4W
Study: NCT00536471

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01347242

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene
Description: transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WAS gene
Study: NCT03616353

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perineural Hydrodissection
Description: The subcutaneous tissues of the ulnar aspect of the wrist at the level of the carpal tunnel will be infiltrated with 2 ml of lidocaine 1% for local anesthetic. Using ultrasound guidance and aseptic technique, the needle will then be angled deep to the median nerve within the carpal tunnel, and 5 ml of a 50%/50% mixture of lidocaine 1% and sensorcaine 0.5% will be injected under pressure. While continuing to use ultrasound guidance and aseptic technique, the needle will then be angled superficial to the median nerve within the carpal tunnel, and 5 ml of a 50%/50% mixture of lidocaine 1% and sensorcaine 0.5% will be injected under pressure. The needle will be returned to its original angle deep to the median nerve, and the syringe will be changed to inject 40 mg Depo-Medrol in 1ml of saline.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticosteroid Injection
Description: The subcutaneous soft tissues of the ulnar aspect of the wrist at the level of the carpal tunnel will be infiltrated with 2 ml of lidocaine 1% for local anesthetic. Using ultrasound guidance and aseptic technique, the needle will then be angled deep to the median nerve within the carpal tunnel, and 40 mg Depo-Medrol in 1ml of saline will be injected into the area deep to the median nerve.